
    
      Phase 1, double-blind, placebo-controlled, dose escalation study to determine the safety,
      tolerability, pharmacokinetics and immunogenicity of single intravenous administrations of
      GGF2 in cohorts of patients with left ventricular dysfunction and symptomatic heart failure.
    
  